The 3-direct-acting antiviral regimen of ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) +/-ribavirin (RBV) has been shown to be safe and effective for the treatment of chronic hepatitis C (CHC) in randomized controlled trials. However, data on real world treatment experience is limited. In Canada, the 3D regimen is approved to treat patients with CHC genotype (GT) 1 including compensated cirrhosis. Aims: The aim of this non-interventional study is to provide evidence of the effectiveness of the 3D regimen in a real world setting across broader clinical practice patient populations. Methods: The Canadian AMBER study is an ongoing, prospective, multi-center, observational cohort study aiming at enrolling 600 treatment-naïve and -experienced GT1 patients with and without compensated cirrhosis. The treatment course was at the discretion of the treating physician, according to the standard of care of the institution. All patients who started therapy from October 2015 up to March 31st, 2016 and for whom a treatment duration of 12 weeks was intended were included in this interim analysis. Effectiveness was defined as having achieved sustained virological response 12 weeks post-treatment (SVR12). Results: The inclusion criteria for this analysis were met by 115 patients. Demographics: 70% male, mean age 55 (SD 10.7), 81% Caucasian, 7% Asian. Disease characteristics: Mode of HCV infection was i.v. drug use in 41%, blood transfusion in 17%, contaminated medical device in 6% and unknown in 28% of patients; GT1a 54%, GT1b 43%, GT1 subtype unknown 3%; 12% had failed previous therapy; 23% had cirrhosis, 8% transition to cirrhosis, Child Pugh B was present in 2 patients. Treatment: 74 (64%) patients had RBV added to their 12 week 3D regimen (96% of GT1a), 41 (36%) patients did not receive RBV (78% of GT1b). See table for comorbidities.
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